Allergy Therapeutics Says Peanut Allergy Drug Meets Primary Safety Goal of Early-stage Study

05:01 AM EST, 12/09/2025 (MT Newswires) -- Allergy Therapeutics (AGY.L) said Tuesday the highest dose of its investigational peanut allergy drug VLP Peanut was safe and well-tolerated in the phase 1/2a trial called Protect. The British biotechnology company added that the preliminary safety data involved both peanut-allergic patients and healthy clinical trial participants. With final dosing in the Protect study already completed, the group will initiate a second interim analysis of data in peanut-allergic patients, with results expected in the first quarter of 2026. Allergy Therapeutics is also preparing for a phase 2b study of VLP Peanut.